21,827 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Simplicity Wealth LLC

Simplicity Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 21,827 shares of the biopharmaceutical company's stock, valued at approximately $1,599,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. West Branch Capital LLC grew its holdings in Gilead Sciences by 1,129.6% during the 1st quarter. West Branch Capital LLC now owns 10,808 shares of the biopharmaceutical company's stock worth $792,000 after acquiring an additional 9,929 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Gilead Sciences by 379.8% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,510,280 shares of the biopharmaceutical company's stock worth $110,628,000 after acquiring an additional 1,195,507 shares in the last quarter. Bell Bank grew its holdings in Gilead Sciences by 3.7% during the 1st quarter. Bell Bank now owns 128,251 shares of the biopharmaceutical company's stock worth $9,394,000 after acquiring an additional 4,618 shares in the last quarter. Busey Bank grew its holdings in Gilead Sciences by 12.1% during the 1st quarter. Busey Bank now owns 6,734 shares of the biopharmaceutical company's stock worth $493,000 after acquiring an additional 729 shares in the last quarter. Finally, Milestone Asset Management LLC acquired a new position in Gilead Sciences during the 1st quarter worth $898,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently weighed in on GILD shares. Cantor Fitzgerald cut their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 7th. Oppenheimer reiterated an "outperform" rating and issued a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Morgan Stanley dropped their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an "equal weight" rating on the stock in a research report on Friday, April 26th. StockNews.com raised shares of Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday, April 27th. Finally, UBS Group lowered their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 17th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $83.69.

Gilead Sciences Stock Up 0.3 %

GILD stock traded up $0.18 during trading hours on Monday, hitting $67.90. The company's stock had a trading volume of 4,719,649 shares, compared to its average volume of 7,296,087. The stock has a 50 day moving average price of $69.09 and a two-hundred day moving average price of $74.85. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 12 month low of $64.33 and a 12 month high of $87.86. The company has a market capitalization of $84.59 billion, a PE ratio of 188.61, a price-to-earnings-growth ratio of 1.37 and a beta of 0.22.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts' consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion during the quarter, compared to analysts' expectations of $6.36 billion. During the same period in the previous year, the company earned $1.37 earnings per share. Gilead Sciences's revenue for the quarter was up 5.3% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.54%. The ex-dividend date is Friday, June 14th. Gilead Sciences's payout ratio is currently 855.56%.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the transaction, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.29% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.